Mehdi, Syed Zafar. Iran unveils second homegrown COVID-19 vaccine. www.aa.com.tr. Anadolu Agency, 7 February 2021. Dostupné online [cit. 22 April 2021].Je zde použita šablona {{Cite news}} označená jako k „pouze dočasnému použití“.
irct.ir
en.irct.ir
IRCT | Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial. en.irct.ir [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném z originálu dne 2021-05-25.
IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial. en.irct.ir [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném z originálu dne 2021-08-30.
irct.ir
IRCT | Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial. www.irct.ir [online]. [cit. 2021-11-16]. Dostupné online.
tehrantimes.com
COVID-19 vaccine Razi Cov Pars starts third clinical trial phase. Tehran Times [online]. 2021-08-27 [cit. 2021-11-16]. Dostupné online. (anglicky)
web.archive.org
IRCT | Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial. en.irct.ir [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném z originálu dne 2021-05-25.
IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial. en.irct.ir [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném z originálu dne 2021-08-30.
